Profit From This Dividend King's Monopoly
by Josh Arnold
Microsoft (MSFT) shares have continued their famous "range bound" nature over the past year, oscillating between $26 and $32. Shares had been punished in recent months based upon the "death of the PC" argument and the idea that the software giant would not be able to reinvent itself in order to compete in the new world of mobile computing. After recent earnings and affirmation from ValueAct Capital, the stock has moved back to nearly $31 in fairly rapid succession at the time of this writing. Given this information, is the move up over for MSFT? This article will take a look at Microsoft's valuation in relation to its prospects and determine whether or not shares deserve your capital. read more »
Get Seeking Alpha notifications with our iPhone App | Android App | iPad App
More on MSFT
Memento Mori Microsoft: Record Breaking Profits Don't Make Problems Disappear - Part 1 by Abu Bakr Hussain
Ubben And ValueAct's Recent Success Makes Microsoft Buy Even More Compelling by Profit Fan
Barbarians At The Gate For Microsoft, But History Will Not Repeat by Tim Travis
Other articles that mention MSFT
How Lumia Could Light Up Nokia's Fortunes by Sneha Shah
Good Times Ahead For Dividend Investors by Ted Waller
Today's Market News To Trade On: 5 Stocks Moving On News by Matthew Smith
Why are you receiving this? You subscribed to real-time article alerts at Seeking Alpha.
If this email was forwarded to you and you wish to subscribe to this email, click here.
Manage your emails:
Get alerts on additional tickers and manage all your email alert choices here
I'm getting too many emails: manage your email alert choices
I'm no longer following MSFT: unsubscribe from all MSFT email alerts
This type of alert isn't helpful to me: unsubscribe from article alerts on MSFT
To ensure you receive these emails in the future, please add account@seekingalpha.com to your address book, contacts or list of safe senders.
Sent by Seeking Alpha, 345 7th Ave. Suite 1400 New York, NY 10001
No comments:
Post a Comment